← Leaderboards
Rugang Zhang
University Of Tx Md Anderson Can Ctr
$23,913,209
Attributed
$24,100,251
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,100,251 · 11
By mechanism
R01$19,639,583 · 7
P50$2,169,109 · 2
P01$2,115,186 · 1
P30$176,373 · 1
Top collaborators
- Xi Chen1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Anil K Sood$29,572,737
- Erik Sulman$6,610,770
- Krishna Pl Bhat$3,427,143
- Meera Nanjundan$2,006,869
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of OvaryMissionInsightCellsBaseGenesInnovationEpithelial Ovarian CancerPublic HealthEpigenetic ProcessMolecularCancer CellUp-RegulationUnited States National Institutes Of HealthMediatingCancer TypeProteinsTumorMouse ModelGenome-WideExperimental StudyPlatinumChemotherapy
Grant awards (67)
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer$521,509
R01 · FY2025 · CA · contact PI
Regulation of tumor recurrence by stress activated neutrophils$500,722
R01 · FY2025 · CA · contact PI
Metabolic basis of ARID1A-mutated ovarian cancer$494,032
R01 · FY2025 · CA · contact PI
Targeting p300 to Overcome PARP inhibitor resistance induced by acidic tumor microenvironment$387,508
P50 · FY2025 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$374,084
R01 · FY2025 · CA · contact PI
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer$495,433
R01 · FY2024 · CA · contact PI
Regulation of tumor recurrence by stress activated neutrophils$489,730
R01 · FY2024 · CA · contact PI
Metabolic basis of ARID1A-mutated ovarian cancer$465,225
R01 · FY2024 · CA · contact PI
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer$439,291
R01 · FY2024 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$360,406
R01 · FY2024 · CA · contact PI
Targeting p300 to Overcome PARP inhibitor resistance induced by acidic tumor microenvironment$340,366
P50 · FY2024 · CA · contact PI
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer$521,509
R01 · FY2023 · CA · contact PI
Research Program: Immunology, Microenvironment and Metastasis$44,895
P30 · FY2023 · CA · contact PI
Project 4: 3D Genomic Basis of Cellular Senescence$421,834
P01 · FY2022 · AG · contact PI
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer$372,161
R01 · FY2022 · CA · contact PI
Metabolic basis of ARID1A-mutated ovarian cancer$363,541
R01 · FY2022 · CA · contact PI
Regulation of tumor recurrence by stress activated neutrophils$325,299
R01 · FY2022 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$306,812
R01 · FY2022 · CA · contact PI
Overcoming platinum resistance in ovarian cancer through BET inhibition.$270,649
P50 · FY2022 · CA · contact PI
Regulation of tumor recurrence by stress activated neutrophils$241,271
R01 · FY2022 · CA · contact PI
Metabolic basis of ARID1A-mutated ovarian cancer$184,954
R01 · FY2022 · CA · contact PI
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer$127,437
R01 · FY2022 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$119,190
R01 · FY2022 · CA · contact PI
Research Program: Immunology, Microenvironment and Metastasis$44,895
P30 · FY2022 · CA · contact PI
Regulation of tumor recurrence by stress activated neutrophils$586,051
R01 · FY2021 · CA · contact PI
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer$509,794
R01 · FY2021 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$434,696
R01 · FY2021 · CA · contact PI
Project 4: 3D Genomic Basis of Cellular Senescence$421,809
P01 · FY2021 · AG · contact PI
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer$263,785
R01 · FY2021 · CA · contact PI
Overcoming platinum resistance in ovarian cancer through BET inhibition.$256,091
P50 · FY2021 · CA · contact PI
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer$221,318
R01 · FY2021 · CA · contact PI
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer$201,907
R01 · FY2021 · CA · contact PI
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer$142,340
R01 · FY2021 · CA · contact PI
Research Program: Immunology, Microenvironment and Metastasis$44,895
P30 · FY2021 · CA · contact PI
Regulation of tumor recurrence by stress activated neutrophils$608,381
R01 · FY2020 · CA · contact PI
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer$509,794
R01 · FY2020 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$434,625
R01 · FY2020 · CA · contact PI
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer$423,225
R01 · FY2020 · CA · contact PI
Project 4: 3D Genomic Basis of Cellular Senescence$421,783
P01 · FY2020 · AG · contact PI
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer$406,125
R01 · FY2020 · CA · contact PI
Overcoming platinum resistance in ovarian cancer through BET inhibition.$234,324
P50 · FY2020 · CA · contact PI
Research Program: Immunology, Microenvironment and Metastasis$41,688
P30 · FY2020 · CA · contact PI
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer$509,794
R01 · FY2019 · CA · contact PI
Project 4: 3D Genomic Basis of Cellular Senescence$421,767
P01 · FY2019 · AG · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$421,585
R01 · FY2019 · CA · contact PI
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer$410,527
R01 · FY2019 · CA · contact PI
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer$393,940
R01 · FY2019 · CA · contact PI
Overcoming platinum resistance in ovarian cancer through BET inhibition.$312,391
P50 · FY2019 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$434,625
R01 · FY2018 · CA · contact PI
Project 4: 3D Genomic Basis of Cellular Senescence$427,993
P01 · FY2018 · AG · contact PI
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer$423,225
R01 · FY2018 · CA · contact PI
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer$406,125
R01 · FY2018 · CA · contact PI
Overcoming platinum resistance in ovarian cancer through BET inhibition.$367,780
P50 · FY2018 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$434,625
R01 · FY2017 · CA · contact PI
Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer$423,225
R01 · FY2017 · CA · contact PI
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer$406,125
R01 · FY2017 · CA · contact PI
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer$434,625
R01 · FY2016 · CA · contact PI
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence$394,250
R01 · FY2016 · CA · contact PI
Role of EZH2 in Epithelial Ovarian Cancer$354,825
R01 · FY2016 · CA · contact PI
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence$383,875
R01 · FY2015 · CA · contact PI
Role of EZH2 in Epithelial Ovarian Cancer$345,488
R01 · FY2015 · CA · contact PI
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence$372,359
R01 · FY2014 · CA · contact PI
Role of EZH2 in Epithelial Ovarian Cancer$335,124
R01 · FY2014 · CA · contact PI
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence$335,486
R01 · FY2013 · CA · contact PI
Role of EZH2 in Epithelial Ovarian Cancer$297,198
R01 · FY2013 · CA · contact PI
Role of BRCA1 Pathway in Regulating Oncogene-Induced Senescence$361,742
R01 · FY2012 · CA · contact PI
Role of EZH2 in Epithelial Ovarian Cancer$316,168
R01 · FY2012 · CA · contact PI